What is DiagnoLung®?
DiagnoLung® is an innovative software programme that supports the diagnosis of lung cancer.
In vitro diagnostic medical devices for the exclusive use of healthcare professionals.
Our products
Amadix has developed the following technological solutions to aid in the early detection of cancer.
DiagnoLung®
in development
40%
How does it work?
DiagnoLung® identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung Cancer
- Biomarker signature.
- Non-invasive test in blood.
- Easy, low cost and a common technique for hospitals and laboratories.
- Confirmation of lung cancer and risk assessment of Incidental Pulmonary Nodules (IPNs) in positive Low Dose Computed Tomography (LDCT) patients and that are incidentally detected.
DiagnoLung® characteristics
Learn more about DiagnoLung®
Intended use
DiagnoLung is intended for:
- The risk assessment for malignancy of Incidental pulmonary nodules (IPNs):
- Incidentally detected
- Positive Low Dose Computed Tomography patients, improving the performance of the Low Dose Computed Tomography screening program
- The confirmation of lung cancer in inconclusive diagnostics.
How can DiagnoLung help you?
In patients with indeterminate pulmonary nodules, between 6 and 30 mm, DiagnoLung would allow physicians to identify patients with likely benign nodules who would become candidates for serial Computed Tomography (CT) monitoring within 2 years.
In a screening context, DiagnoLung is indicated to confirm positive Low Dose Computed Tomography (LDCT) results that may indicate the presence of lung cancer and should be confirmed with an invasive test (biopsies).
Performed in conjunction with a biopsy, DiagnoLung can be used to confirm cancer in patients with inconclusive cytological and histological analysis (in a clinical context, it is not possible to confirm the diagnosis in up to 50% of first bronchoscopies).
It is not a replacement for diagnostic methods or the monitoring of high-risk individuals (50 to 80 years old and in fairly good health, who currently smoke or who have quit in the past 15 years and have at least a 20 pack/year smoking history).
PancreaDix®
What is PancreaDix®?
En desarrollo
40%
What is PancreaDix®?
PancreaDix® is an innovative, non-invasive signature in blood for:
- Confirming a Pancreatic cancer diagnosis.
- Detecting pre-malignant lesions that will evolve to cancer.
- Performing a differential diagnosis between Pancreatic cancer and other pathologies such as chronic pancreatitis or neuroendocrine tumors.
How does it work?
PancreaDix® identifies and measures biomarkers which are differentially expressed in blood samples of individuals with Pancreatic Cancer (PaC).
- Genetic biomarkers.
- Non-invasive test in plasma.
- Easy, low cost and a common technique for hospitals and laboratories.
- Confirming Pancreatic cancer diagnosis, identifying benign vs. malign pancreatic cysts to avoid unnecessary surgeries and differential diagnosis between Pancreatic cancer and other pathologies.
PancreaDix® characteristics
Learn more about PancreaDix®
Intended use
PancreaDix® will typically be prescribed by the Gastroenterologist or the General Practitioner to patients with:
- Incidental findings in the pancreas
- Symptoms compatible with pancreatic cancer.
- Case of chronic pancreatitis or neuroendocrine tumors to confirm that it is not cancer.
- Case of cysts to diagnose their potential malignancy to proceed with surgery or not.
- Inconclusive biopsies or images.
- High-risk for Pancreatic Cancer, recommended for screening (this group of patients should be included in future studies).
How can PancreaDix® help you?
PancreaDix® will improve the early detection of premalignant and malignant lesions of pancreatic cancer and it enables physicians to better manage patients with pancreatic cancer and other pancreatic pathologies.
Clinical study
We are conducting a national clinical study to further validate this technology.
If you want more details, please contact us.
PreveCol® Software
What is PreveCol® Software?
PreveCol® Software is an innovative tool based on an algorithm for the early detection of colorectal cancer and/or advanced adenomas, using the analysis of biomarkers present in the blood and the clinical characteristics of patients.
How does it work?
PreveCol® Software uses an algorithm that, through biomarkers and clinical characteristics of patients, detects advanced neoplastic lesions in addition to colorectal cancer even before the first symptoms appear.
It has been developed and validated entirely by Amadix through prospective case-control clinical studies and real-world screening in European populations, as they have been conducted in Spain, Poland, and Germany.
PreveCol® Software has been recognised by the FDA with the Breakthrough Device designation, which recognises it as a medical device that offers a superior clinical solution through innovative technology compared to any other on the US market. It cúrrenle has the CE mark.
